CAMK1D

CAMK1D is a Ca²⁺/calmodulin-dependent serine/threonine kinase that transduces calcium signals into diverse cellular responses including transcriptional regulation, innate immune cell activation, energy homeostasis, and apoptosis resistance. Upon calcium influx and activation by the upstream kinase CaMKK-alpha, CAMK1D phosphorylates CREB to drive CRE-dependent transcription—a mechanism operative in granulocyte activation, ghrelin-stimulated AgRP/NPY neuropeptide expression controlling food intake, and cancer cell stemness—and phosphorylates AMPK at Thr172 to activate PINK1-dependent mitophagy (PMID:11050006, PMID:37277610, PMID:41419457, PMID:41510165). In neutrophils, CAMK1D is required for fMLP-induced ROS production, migration, adhesion, and phagocytosis (PMID:15840691), while in tumor cells Fas-receptor signaling activates CAMK1D to phosphorylate and inhibit caspases-3, -6, and -7, conferring resistance to immune-mediated killing (PMID:32665263). CAMK1D also regulates hepatic glucose metabolism through control of CRTC2 nuclear localization, protects proximal tubule mitochondria from diabetic injury via ApoJ-mediated signaling, and contributes to Aβ-induced tau hyperphosphorylation in cortical neurons (PMID:23840313, PMID:39271683, PMID:34946752).

1. 2000 High

   Identification of CKLiK/CAMK1D as a novel Ca²⁺/calmodulin-dependent kinase established that a previously unknown member of the CaMK-I family is expressed preferentially in granulocytes, is activated by CaMKK-alpha, and can phosphorylate CREM and activate CREB-dependent transcription.

   Evidence In vitro kinase assay on CREM, CaMKK-alpha co-activation, CRE-luciferase reporter, ionomycin stimulation in stably transfected cells

   PMID:11050006

   Open questions at the time

   • Endogenous substrates in granulocytes not identified
   • Upstream signals beyond calcium ionophore not characterized
   • Physiological role in innate immunity not yet tested
2. 2004 Medium

   Discovery of two CAMK1D isoforms with opposing effects on apoptosis (one pro-apoptotic, one anti-apoptotic) revealed that alternative C-terminal regions confer distinct functional outputs, with only the CREB-activating isoform being anti-apoptotic.

   Evidence Overexpression of individual isoforms in murine erythroleukemia cells, low-serum apoptosis assay, CRE-luciferase reporter

   PMID:14980499

   Open questions at the time

   • Isoform-specific substrates not identified
   • Single cell line model; not confirmed in primary hematopoietic cells
   • Mechanism linking CREB activation to survival not dissected
3. 2005 High

   Demonstrating that peptide-mediated inhibition of CAMK1D blocks fMLP-induced ROS production, migration, adhesion, and phagocytosis in granulocytes established CAMK1D as a required effector of innate immune cell activation downstream of physiological chemoattractants.

   Evidence Cell-permeable inhibitor peptide (CKLiK297-321) in primary human granulocytes, ROS/migration/adhesion/phagocytosis assays

   PMID:15840691

   Open questions at the time

   • Direct substrates mediating each granulocyte phenotype unknown
   • Genetic knockout confirmation not performed
   • Specificity of peptide inhibitor for CAMK1D over other CaMK-I family members not fully excluded
4. 2008 Medium

   Finding CAMK1D amplification in basal-like breast cancer and showing that its overexpression drives proliferation and EMT extended the kinase's role from immune cells to oncogenic signaling, suggesting kinase activity can reprogram epithelial plasticity.

   Evidence Genomic copy number and expression analysis, engineered overexpression in MCF10A-type cells, proliferation/migration/invasion assays

   PMID:19383354

   Open questions at the time

   • Direct kinase substrates mediating EMT not identified
   • Kinase-dead control not used
   • Not tested in loss-of-function in breast cancer cells
5. 2013 Medium

   Showing that CAMK1D knockdown in primary hepatocytes alters CRTC2 nuclear localization in response to glucagon linked the kinase to hepatic glucose metabolism and provided a functional connection to the CDC123/CAMK1D type 2 diabetes GWAS locus.

   Evidence siRNA knockdown in primary human hepatocytes, CRTC2 nuclear localization and glycogen storage assays

   PMID:23840313

   Open questions at the time

   • Whether CAMK1D directly phosphorylates CRTC2 or acts indirectly not determined
   • In vivo hepatic phenotype not examined
   • Relationship between GWAS SNP and CAMK1D expression level in hepatocytes not established
6. 2014 High

   Demonstrating allele-specific enhancer activity at rs11257655 with differential FOXA1/FOXA2 binding in human islets provided a mechanistic basis for how the T2D GWAS variant at the CAMK1D locus may alter gene regulation in disease-relevant tissues.

   Evidence Luciferase reporter, EMSA, supershift, allele-specific ChIP in human islets, chromatin state analysis

   PMID:25211022

   Open questions at the time

   • Whether the enhancer regulates CAMK1D versus CDC123 not definitively resolved
   • Effect of the variant on CAMK1D protein level or activity in islets not measured
   • Functional consequence for insulin secretion not tested
7. 2020 High

   Identification of caspases-3, -6, and -7 as direct CAMK1D substrates whose phosphorylation blocks their activation revealed a mechanism by which tumor cells resist CTL-mediated and anti-PD-L1 immune killing, establishing CAMK1D as a druggable node in immune evasion.

   Evidence Genetic screen in PD-L1+ myeloma-CTL co-culture, Co-IP, phosphorylation assays, Fas-receptor stimulation, pharmacological inhibition, in vivo colorectal cancer model

   PMID:32665263

   Open questions at the time

   • Specific phosphorylation sites on caspases not mapped
   • Whether CAMK1D-mediated caspase inhibition operates in non-tumor contexts unknown
   • Structural basis of CAMK1D-caspase interaction not resolved
8. 2021 Medium

   Pharmacological inhibition of CAMK1D prevented Aβ-induced tau hyperphosphorylation in primary cortical neurons, positioning the kinase upstream of pathological tau modification without affecting Aβ-induced toxicity per se.

   Evidence Primary mouse cortical neurons, Aβ treatment, pharmacological CAMK1D inhibitors, tau phosphorylation and viability assays

   PMID:34946752

   Open questions at the time

   • Whether CAMK1D directly phosphorylates tau or acts through intermediary kinases not determined
   • Inhibitor selectivity across CaMK family not fully characterized
   • In vivo relevance in neurodegeneration models not tested
9. 2023 High

   Conditional knockout of Camk1d in AgRP neurons abolished ghrelin-induced food intake and protected from diet-induced obesity by attenuating CREB phosphorylation and AgRP/NPY neuropeptide expression, establishing CAMK1D as a required mediator of hypothalamic energy homeostasis.

   Evidence Global and AgRP-neuron-specific Camk1d KO mice, ghrelin challenge, food intake, body weight on high-fat diet, CREB phosphorylation and neuropeptide expression

   PMID:37277610

   Open questions at the time

   • Whether CAMK1D directly phosphorylates CREB at Ser133 or acts through an intermediary in AgRP neurons not demonstrated in vitro
   • Contribution of CAMK1D in other neuron types to energy balance not explored
   • Downstream targets beyond AgRP/NPY not characterized
10. 2024 High

    Multi-omic analysis of diabetic kidney disease revealed that podocyte-derived ApoJ activates CAMK1D signaling in proximal tubule cells to attenuate mitochondrial fission, identifying a paracrine axis through which CAMK1D preserves mitochondrial integrity under diabetic stress.

    Evidence Conditional KLF6 overexpression in podocytes (murine DKD model), snRNA-seq, snATAC-seq, mass spectrometry, mitochondrial fission assay

    PMID:39271683

    Open questions at the time

    • Direct CAMK1D substrates mediating mitochondrial fission inhibition not identified
    • Whether CAMK1D acts on DRP1 or other fission machinery not tested
    • Mechanism of ApoJ-to-CAMK1D signal transduction not resolved
11. 2025 Medium

    Identification of AMPK as a direct CAMK1D substrate (phosphorylated at Thr172) linked the kinase to PINK1-dependent mitophagy, explaining how CAMK1D supports prostate cancer stem-like cell expansion and enzalutamide resistance.

    Evidence Co-IP of CAMK1D-AMPK, Thr172 phosphorylation assay, PINK1/Parkin mitophagy assay, siRNA knockdown, orthotopic PCa models

    PMID:41419457

    Open questions at the time

    • Whether CAMK1D is the dominant AMPK Thr172 kinase in non-cancer contexts not addressed
    • Single-lab finding; independent replication needed
    • Structural basis for CAMK1D selectivity toward AMPK versus known AMPK kinases (LKB1, CaMKK2) not examined

• The full substrate repertoire of CAMK1D remains undefined, and it is unresolved whether its diverse physiological roles—immune activation, energy homeostasis, apoptosis resistance, mitochondrial maintenance—are mediated primarily through CREB, AMPK, and caspases or additional substrates, and whether isoform-specific functions dictate tissue-specific outcomes.
• Comprehensive phosphoproteomics to identify the full CAMK1D substrate landscape has not been performed
• No crystal structure of CAMK1D is available to explain substrate selectivity
• Isoform-specific signaling outputs have not been resolved beyond the initial 2004 observation